WhereIsAtlas · Pharmaceuticals

What Happened to Ranbaxy?

India's generic-drug giant was the affordable-medicine miracle the world trusted — until an investigator proved it had faked half its own safety data.

Ranbaxy built India's generics empire on fabricated safety data, pleaded guilty to a historic $500M fraud in 2013, and was absorbed into Sun Pharma — while its executives scattered across the industry undeterred.

The chase under the stairs

On March 18, 2013, a young, tattooed FDA investigator named Peter Baker arrived at the Wockhardt manufacturing plant in Waluj, India. The facility was massive, pristine, and responsible for manufacturing sterile injectable drugs for American cancer and heart patients. Baker's instincts told him to ignore the rehearsed slide shows and guided tours meant to run down the clock.

On his second day, walking down a quiet corridor, Baker spotted a plant employee walking a little too quickly, clutching a clear garbage bag. When their eyes locked, the man bolted. Baker and his colleague gave chase beneath the fluorescent lights. The employee sprinted down a side door, hurled the bag onto a pile of trash in a dark stairwell, scrambled up a concrete maze, and vanished. Inside the bag, Baker discovered torn, half-shredded records of the company's insulin products. They revealed that the vials were contaminated with black metallic particles, and that the firm had been secretly clearing these potentially lethal batches for release to patients — hiding the failure logs from the FDA while manufacturing the tainted drugs on a secret, uninspected line.

The whispered reality

Years earlier, an information scientist named Dinesh Thakur sat in the Gurgaon headquarters of Ranbaxy Laboratories, India's largest generic drug developer. He had left a prestigious career at Bristol-Myers Squibb in the United States, believing he was helping to build an Indian Pfizer that would make lifesaving cures affordable to the world.

Instead, he encountered chaos. When he began asking questions about data discrepancies, Arun Kumar, a regulatory affairs official, casually told him that everyone knew what the reality was and where the gaps were. Thakur assigned his team to conduct a global retrospective audit. The findings were horrifying: Ranbaxy was systematically fabricating the data used to prove its drugs were safe and equivalent to brand-name medications. To get quick approvals, scientists substituted lower-purity ingredients, faked dissolution tests, backdated documents in steam rooms to make them look aged, and even crushed up brand-name pills into capsules to test them in place of their own failing formulations.

Thakur's team estimated that Ranbaxy had faked over half of the dossiers it submitted to the US FDA, and essentially all of the data it submitted to Indian regulators, who never examined the paperwork anyway.

The boardroom confrontation

In October 2004, Thakur's boss, the reputable physician Dr. Rajinder 'Raj' Kumar, stood in Ranbaxy's New Delhi boardroom. He presented a 24-slide PowerPoint detailing the company's systemic, global fraud to a silent group of executives. Instead of ordering a recall, one board member turned to the CEO and asked whether the data could not be buried. The CEO demanded that every copy of the presentation be destroyed and the laptop used to create it be broken down piece by piece.

Raj Kumar resigned in protest within two days. Thakur was left unprotected. Soon after, Ranbaxy's 'secret police' targeted him, hacking into his servers and planting IP address logs to frame him for browsing pornography in an attempt to destroy his credibility and force him out.

Do not give to FDA

Thakur resigned, fled to the United States, and began a double life. Living in a cheerless New Jersey rental on dwindling savings, he anonymously emailed the FDA under the pseudonym 'Malvinder Singh,' pleading with them to stop the crime. He eventually filed a sealed whistleblower lawsuit with the help of attorney Andrew Beato.

On February 14, 2007, federal agents swarmed Ranbaxy's US headquarters in New Jersey, confiscating computers and herding weeping employees into conference rooms. In the office of regulatory VP Abha Pant, investigators hit a goldmine: a secret file detailing Ranbaxy's years of failed tests on its acne drug, Sotret. Across the cover page, in bold letters, was written: 'Do Not Give to FDA.'

The great escape

At the center of the empire sat Malvinder Mohan Singh, the brash, ultra-stylish billionaire heir to the Ranbaxy dynasty. He wore bespoke suits, drove a $100,000 Mercedes, and treated corporate life as a battlefield from The Art of War.

Knowing the US Department of Justice was closing in, Malvinder engineered a highly secretive, code-named transaction to sell majority control of Ranbaxy to the Japanese pharmaceutical giant Daiichi Sankyo for billions of dollars. He stripped the damning self-assessment reports from the due-diligence data rooms and forced his legal team to lie to Daiichi's formal, trusting executive Tsutomu Une. When Ranbaxy's intellectual-property lawyer suffered a crisis of conscience and threatened to tell the Japanese the truth, Malvinder hauled him into his office and snarled that he knew where he lived. The lawyer resigned the next day. In November 2008 the deal closed, and the Singh brothers pocketed over two billion dollars.

The reckoning

On May 13, 2013, in a Baltimore federal courtroom, Ranbaxy pleaded guilty to multiple felony charges of faking data and agreed to a historic $500 million fine. Thakur was publicly revealed as the whistleblower and was awarded a staggering $48 million — becoming a celebrated hero in the United States and a branded anti-national pariah in India.

Yet while the corporation pleaded guilty, not a single executive was prosecuted. Instead, a massive corporate diaspora occurred: dozens of Ranbaxy executives who had mastered data manipulation left the tarnished company and landed high-level jobs across the global generic drug industry. Regulators realized that to find the next fraud, they would simply have to follow where the former Ranbaxy executives went.

What happened after 2013

In 2014, the disgraced Ranbaxy — its value destroyed and its core business sold off — was absorbed by India's Sun Pharma in a deal valued at roughly $4 billion. The brand name disappeared, folded into Sun's generics arm. The $500 million fine it paid remains one of the largest settlements at the time in drug-fraud history.

Malvinder Mohan Singh's luck eventually ran out too. Years later, after a litany of asset-freezing, debt and legal battles over his other holdings, he and his brother were arrested in India in 2019 over allegations of siphoning funds. The heir who had thought he outsmarted both the US Justice Department and the Japanese found himself stripped of the fortune he had guarded so fiercely.

And the industry he left behind never fully recovered its trust. Regulators learned that the systemic fraud was not one company's aberration but a symptom of a generic-drug boom in which cheap, lifesaving medicines were manufactured on a foundation of fabricated data. The name Ranbaxy is gone, but the lesson endures: the fraud that sold the world affordable medicine was, in the end, a story about who trusted whom — and what happened when that trust collapsed.

Sources